Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval    source : Cytosorbents.com    save search
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Published: 2021-10-12 (Crawled : 23:00) - cytosorbents.com
CTSO | $0.8026 0.2% 0.2% 46K twitter stocktwits trandingview |
Health Technology
 | | O: -1.3% H: 0.0% C: -10.38%
fda drug device iot cardio trial approval
Gainers vs Losers
68% 32%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K twitter stocktwits trandingview |
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.